Business
Stem Cell Therapy
Organoid
Stem Cell and CDMO Business
R&D
Core Technology
Press Release
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Kangstem Biotech Starts Commercialization of Organoid Sales... Implementing mass production system base with standardized quality
05
2025.12
- It opens up various orders and sales possibilities with perfect reproduction of functions close to real human skin
Kangstem Biotech announced that it has begun full-scale commercialization of its organoid technology platform by establishing testing methods through collaborative R&D and launching organoid product supply to customers. The company aims to expand organoid-related revenue as a part of its strategy to differentiate its technology.
The company recently supplied skin organoids to a large domestic conglomerate specializing in lifestyle and health products for the evaluation of drug absorption. Separately, Kangstem Biotech signed a joint research agreement with a leading domestic institute focused on basic and translational research to develop a hair follicle organoid–based HTS method. Additionally, the company is conducting a preliminary testing with a large health supplement manufacturer on substances that may help prevent and treat hair loss. With these developments, Kangstem Biotech has entered into the commercialization phase, generating revenue not only through organoid-based screening services but also through direct organoid product supply.
A company representative stated, “Unlike conventional organoids that have an inverted inside-out structure and therefore cannot model transdermal delivery through the epidermis, our organoids have a flat, skin-like architecture, enabling evaluation of both transdermal and systemic delivery routes.” And the representative added, “This provides a major advantage in assessing drug absorption, which is difficult with simply layered artificial skin models. Furthermore, our organoids fully reproduce human skin structures—such as hair follicles, sebaceous glands, nerves, and melanocytes—and we have established a mass-production system capable of maintaining consistent, standardized quality for our organoids.”
Kangstem Biotech’s organoid platform has attracted strong interest and specific collaboration requests from domestic and global pharmaceutical, biotech, and cosmetic companies due to its unique advantages, including:
▲ Implementation of a 3D structure and functions highly similar to actual human skin, enabling accurate replication of drug or material effects;
▲ Formation of advanced, complex tissues, including epidermis, subcutaneous fat, hair follicles, blood vessels, and immune cell responses;
▲ Ability to test various mechanisms—such as absorption, anti-inflammatory effects, anti-aging effects, pigmentation, and hair follicle activity—all within a single platform for compounds under development by clients.
According to recent market analyses, the global organoid market is expected to grow rapidly from USD 1.1 billion in 2025 to USD 6.3 billion by 2035. Following the U.S. FDA’s announcement in April 2025 of a gradual phase-out of nonclinical animal testing, global interest in organoids and discussions on their applications have continued to increase significantly.
For more details, please refer to the link below
https://www.yakup.com/news/index.html?mode=view&cat=12&nid=320082
▲ Photo of hair organoid being cultured at Kangstem Biotech Laboratory